文献速递生殖医学

使用8-OHdG免疫检测法测定人精子DNA氧化定量与阈值的准确性

Accuracy of human sperm DNA oxidation quantification and threshold determination using an 8-OHdG immuno-detection assay.
PubMed 文献 · Hum Reprod · 2018-01-01

本前瞻性研究比较了四种方案(I-IV)和三种免疫检测方法,以确定评估人精子8-OHdG含量的最适方法,并验证用于常规诊断的优化方法。在80例患者中,区分阈值为65.8%的8-OHdG阳性精子细胞和552任意单位的平均荧光强度(MIF)。方案III在检测重复性、特异性、敏感性和稳定性方面最具区分度,39%的精子DNA氧化值「病理」的受试者精液参数正常。

要点

  • 区分阈值为65.8%的8-OHdG阳性精子细胞和MIF 552任意单位。
  • 方案III在检测精子参数改变(尤其白细胞精子症)方面最具区分度。
  • 39%的精子DNA氧化值「病理」的受试者精液参数正常。

核心结论

  • 本研究首次验证了确定人精子DNA氧化区分阈值的方案,该检测应可用于与氧化应激相关的男性因素不育的诊断。

研究设计与样本

  • 前瞻性研究,对四种方案(I-IV)进行方法内和方法间比较,并比较三种免疫检测方法(免疫细胞化学、荧光显微镜和流式细胞术)。
  • 纳入80例患者(年龄35±1岁,均值±标准误),其中精液参数正常者40例,参数异常者(坏死和/或弱精和/或畸形和/或白细胞精子症)40例。

主要发现

  • 使用方案III时,8-OHdG值与精子参数之间显示显著的Pearson和Spearman正相关。
  • MIF与BMI和白细胞浓度呈显著高正相关。
  • 39%的精子DNA氧化值「病理」的受试者为精液参数正常。

关键数值与推荐

  • 区分阈值为65.8%的8-OHdG阳性精子细胞和平均荧光强度(MIF)552任意单位。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究未评估少精症人群,因材料不足无法进行比较;但统计分析中已考虑精子浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can a discriminant threshold be determined for human sperm DNA oxidation? SUMMARY ANSWER: A discriminant threshold was found with 65.8% of 8-hydroxy-2'-deoxyguanosine (8-OHdG)-positive sperm cells and a mean intensity of fluorescence (MIF) of 552 arbitrary units. WHAT IS KNOWN ALREADY: Oxidative stress is known to interfere with sperm quality and fertilizing capacity. However, current practice does not include the routine determination of oxidative DNA damage in spermatozoa; optimized consensus protocols are lacking and no thresholds of normality have been established. STUDY DESIGN, SIZE, DURATION: Intra- and inter-method comparisons between four protocols (I-IV) were conducted to determine the most relevant and efficient means of assessing human sperm 8-OHdG content. Tests of assay repeatability, specificity, sensitivity and stability were performed to validate an optimized methodology for routine diagnostic use. PARTICIPANTS/MATERIALS, SETTING, METHODS: This prospective study compared three immuno-detection methods including immunocytochemistry, fluorescence microscopy and flow cytometry. Sperm DNA oxidation for 80 patients was determined relative to semen parameters and clinical conditions, using the selected immuno-detection protocol in comparison with a commercial kit. These patients (age 35 ± 1 years: mean ± SEM) presented with normozoospermic (n = 40) or altered parameters (necro- or/and astheno- or/and teratozoospermia or/and leukocytospermia). MAIN RESULTS AND THE ROLE OF CHANCE: Significant positive Pearson and Spearman correlations were determined for 8-OHdG values and sperm parameters using protocol III. A notable high and positive correlation was revealed for MIF with BMI and leukocyte concentration. Protocol III was the most discriminating method regarding assay repeatability, specificity, sensitivity, stability and reliability for sperm parameter alterations, in particular leukocytospermia according to parametric or non-parametric tests, effect-size determinations and factorial analysis such as principal component analysis and factor discriminant analysis. Of interest is that 39% of the subjects with 'pathological' sperm DNA oxidation values were normozoospermic. LIMITATIONS, REASONS FOR CAUTION: The oligozoospermic population was not evaluated in this study because insufficient material was available to carry out the comparisons. However, spermatozoa concentration was taken into account in the statistical analysis. WIDER IMPLICATIONS OF THE FINDINGS: Our study is the first validation of a protocol to determine a discriminant threshold for human sperm DNA oxidation. The protocol's detection accuracy for 8-OHdG human sperm DNA residues, stability over time, and relationship to human sperm quality were demonstrated. The assay should find application in the diagnosis of male factor infertility associated with oxidative stress. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by institutional grants from the CNRS, INSERM and Université Clermont Auvergne (to J.R.D.) and by Clermont-Ferrand Hospital-CECOS research funds (to L.J. and F.B.). P.G., A.M., R.J.A. and J.D. are, respectively, CEO, scientific director and scientific advisors of a US-based biotech company (Celloxess, Princeton, NJ, USA) involved in preventative medicine with a focus on the generation of antioxidant oral supplements.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vorilhon S, Brugnon F, Kocer A, et al. Accuracy of human sperm DNA oxidation quantification and threshold determination using an 8-OHdG immuno-detection assay. Hum Reprod. 2018. PMID: 29579272. doi:10.1093/humrep/dey038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。